Rockwell Medical Technologies Prices $35.0 Million Public Offering of Common Stock

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WIXOM, Mich., May 15, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it has priced an underwritten public offering of 11,475,410 shares of its common stock at a price to the public of $3.05 per share for gross proceeds of $35.0 million. The net proceeds from the sale of the shares, after deducting the underwriters’ discounts and other estimated offering expenses payable by Rockwell, will be approximately $32.8 million. Rockwell has also granted the underwriters a 30-day option to purchase up to an additional 1,721,312 shares of common stock offered in the public offering to cover overallotments, if any.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC